Article
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models.
Neuro-oncology - 25 Mar 2021
Vitanza Nicholas A, Biery Matt C, Myers Carrie, Ferguson Eric, Zheng Ye, Girard Emily J, Przystal Justyna M, Park Giulia, Noll Alyssa, Pakiam Fiona, Winter Conrad A, Morris Shelli M, Sarthy Jay, Cole Bonnie L, Leary Sarah E S, Crane Courtney, Lieberman Nicole A P, Mueller Sabine, Nazarian Javad, Gottardo Raphael, Brusniak Mi-Youn, Mhyre Andrew J, Olson James M
Abstract excerpt
BACKGROUND: Diffuse midline gliomas (DMGs), including diffuse intrinsic pontine gliomas (DIPGs), have a dismal prognosis, with less than 2% surviving 5 years postdiagnosis. The majority of DIPGs and all DMGs harbor mutations altering the epigenetic regulatory histone tail (H3 K27M). Investigations addressing DMG epigenetics have identified a few promising drugs, including the HDAC inhibitor (HDACi) panobinostat....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.